AR114977A1 - Cristales de derivado de benzoxazol - Google Patents
Cristales de derivado de benzoxazolInfo
- Publication number
- AR114977A1 AR114977A1 ARP190101746A ARP190101746A AR114977A1 AR 114977 A1 AR114977 A1 AR 114977A1 AR P190101746 A ARP190101746 A AR P190101746A AR P190101746 A ARP190101746 A AR P190101746A AR 114977 A1 AR114977 A1 AR 114977A1
- Authority
- AR
- Argentina
- Prior art keywords
- benzoxazole derivative
- derivative crystals
- crystals
- benzoxazole
- heptan
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 title 1
- FJBDQIRRDKSQTK-UHFFFAOYSA-N 1-[[2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-(1,3-thiazol-2-yl)-1,3-benzoxazol-4-yl]oxy]-1,1-difluoro-2-methylpropan-2-ol Chemical compound C12CN(CC(N1)C2)C=1OC2=C(N=1)C(=CC=C2C=1SC=CN=1)OC(C(C)(O)C)(F)F FJBDQIRRDKSQTK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporcionan cristales de 1-((2-(3,6-diazabiciclo[3.1.1]heptan-3-il)-7-(tiazol-2-il)benzo[d]oxazol-4-il)oxi)-1,1-difluoro-2-metil propan-2-ol que está representado por la fórmula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018121413 | 2018-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114977A1 true AR114977A1 (es) | 2020-11-11 |
Family
ID=68986306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101746A AR114977A1 (es) | 2018-06-27 | 2019-06-24 | Cristales de derivado de benzoxazol |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11512091B2 (es) |
| EP (1) | EP3816167B1 (es) |
| JP (1) | JP6831496B2 (es) |
| KR (1) | KR20210024551A (es) |
| CN (1) | CN112351986B (es) |
| AR (1) | AR114977A1 (es) |
| AU (1) | AU2019293572B2 (es) |
| BR (1) | BR112020026202A2 (es) |
| CA (1) | CA3104829A1 (es) |
| ES (1) | ES2926469T3 (es) |
| IL (1) | IL279763B2 (es) |
| MX (1) | MX2020014317A (es) |
| NZ (1) | NZ772151A (es) |
| TW (1) | TWI788580B (es) |
| WO (1) | WO2020004517A1 (es) |
| ZA (1) | ZA202100484B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020004521A1 (ja) * | 2018-06-27 | 2020-01-02 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 炎症性疾患、自己免疫疾患、線維化疾患、及びがん疾患の治療剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2570769T3 (es) * | 2008-12-19 | 2016-05-20 | Leo Pharma As | Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas |
| JP6345664B2 (ja) | 2013-07-10 | 2018-06-20 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 新規ｐｄｅ４阻害剤 |
| WO2018104060A1 (en) * | 2016-12-05 | 2018-06-14 | Telefonaktiebolaget Lm Ericsson (Publ) | Service continuity after an application server fallback |
| PL3560925T3 (pl) | 2016-12-26 | 2021-12-20 | Meiji Seika Pharma Co., Ltd. | Nowy związek i jego dopuszczalna farmaceutycznie sól |
| WO2020004521A1 (ja) | 2018-06-27 | 2020-01-02 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 炎症性疾患、自己免疫疾患、線維化疾患、及びがん疾患の治療剤 |
-
2019
- 2019-06-24 AR ARP190101746A patent/AR114977A1/es unknown
- 2019-06-27 BR BR112020026202-1A patent/BR112020026202A2/pt unknown
- 2019-06-27 CA CA3104829A patent/CA3104829A1/en active Pending
- 2019-06-27 TW TW108122583A patent/TWI788580B/zh active
- 2019-06-27 WO PCT/JP2019/025512 patent/WO2020004517A1/ja unknown
- 2019-06-27 CN CN201980042488.5A patent/CN112351986B/zh active Active
- 2019-06-27 JP JP2020527613A patent/JP6831496B2/ja active Active
- 2019-06-27 MX MX2020014317A patent/MX2020014317A/es unknown
- 2019-06-27 US US17/255,584 patent/US11512091B2/en active Active
- 2019-06-27 ES ES19826594T patent/ES2926469T3/es active Active
- 2019-06-27 EP EP19826594.4A patent/EP3816167B1/en active Active
- 2019-06-27 AU AU2019293572A patent/AU2019293572B2/en active Active
- 2019-06-27 KR KR1020217001557A patent/KR20210024551A/ko not_active Application Discontinuation
- 2019-06-27 IL IL279763A patent/IL279763B2/en unknown
- 2019-06-27 NZ NZ772151A patent/NZ772151A/en unknown
-
2021
- 2021-01-22 ZA ZA2021/00484A patent/ZA202100484B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2020004517A1 (ja) | 2021-02-25 |
| EP3816167A4 (en) | 2021-12-15 |
| IL279763A (en) | 2021-03-01 |
| EP3816167A1 (en) | 2021-05-05 |
| AU2019293572A1 (en) | 2021-02-11 |
| EP3816167B1 (en) | 2022-08-03 |
| AU2019293572B2 (en) | 2024-01-04 |
| ZA202100484B (en) | 2022-08-31 |
| US20210155630A1 (en) | 2021-05-27 |
| CN112351986B (zh) | 2023-04-18 |
| CN112351986A (zh) | 2021-02-09 |
| KR20210024551A (ko) | 2021-03-05 |
| NZ772151A (en) | 2024-03-22 |
| TW202000664A (zh) | 2020-01-01 |
| TWI788580B (zh) | 2023-01-01 |
| US11512091B2 (en) | 2022-11-29 |
| JP6831496B2 (ja) | 2021-02-17 |
| IL279763B1 (en) | 2023-10-01 |
| BR112020026202A2 (pt) | 2021-03-23 |
| ES2926469T3 (es) | 2022-10-26 |
| CA3104829A1 (en) | 2020-01-02 |
| IL279763B2 (en) | 2024-02-01 |
| MX2020014317A (es) | 2021-03-09 |
| WO2020004517A1 (ja) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058005A1 (es) | Derivados fluorados de 4-(2- amino-1-hidroxietil) fenol como agonistas del receptor beta 2 adrenergico | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
| PE20161371A1 (es) | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas | |
| AR080779A1 (es) | Pirrolopirazina como inhibidores quinasa, composiciones farmaceuticas que los contienen y sus aplicaciones | |
| ECSP088773A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
| AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
| MA42341A1 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| PE20181487A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
| PE20142376A1 (es) | Fluormetil-5,6-dihidro-4h-[1,3]oxazinas | |
| PE20091099A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
| AR043940A1 (es) | Inhibidores de sulfonamidas heterociclicas que contienen fluor- y trifluoralquilo de la produccion de beta amiloides y derivados de los mismos | |
| PE20141540A1 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| CL2021001877A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| PE20080359A1 (es) | Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r | |
| AR074459A1 (es) | Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| AR074622A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos | |
| BRPI0817096B8 (pt) | análogo de tiazolidinodiona e composição farmacêutica que o compreende | |
| AR074696A1 (es) | Derivados heterociclicos de isoxazol para su uso como reguladores del crecimiento de plantas. | |
| PE20220961A1 (es) | Moduladores de la via de respuesta integrada al estres | |
| AR080699A1 (es) | Pirrolopirazinas como inhibidores de jak y syk | |
| ECSP109919A (es) | Compuesto de piridacina cristalina | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp |